RIVAROXABAN PROPHARM 10 MG

البلد: إسرائيل

اللغة: الإنجليزية

المصدر: Ministry of Health

العنصر النشط:

RIVAROXABAN

متاح من:

PROPHARM LTD

ATC رمز:

B01AF01

الشكل الصيدلاني:

FILM COATED TABLETS

تركيب:

RIVAROXABAN 10 MG

طريقة التعاطي:

PER OS

نوع الوصفة الطبية :

Required

المصنعة من قبل:

ADALVO LIMITED, MALTA

المجال العلاجي:

RIVAROXABAN

الخصائص العلاجية:

Prevention of venous thromboembolism (VTE) in adult patients undergoing elective hip or knee replacement surgery. Prevention of recurrent deep vein thrombosis (DVT) and pulmonary embolism (PE), adults (following completion of at least 6 months therapy for DVT or PE).

تاريخ الترخيص:

2023-12-20

نشرة المعلومات

PATIENT PACKAGE INSERT IN ACCORDANCE WITH
THE PHARMACISTS’ REGULATIONS (PREPARATIONS) – 1986
The medicine is dispensed with a doctor’s prescription only
RIVAROXABAN PROPHARM 10 MG
FILM-COATED TABLETS
ACTIVE INGREDIENT
Each tablet contains:
rivaroxaban 10 mg
Inactive ingredients and allergens in the preparation: See section
section 2 “Important information
regarding some of the ingredients of the medicine” and section 6
“Further information”.
READ THIS LEAFLET CAREFULLY IN ITS ENTIRETY BEFORE USING THE MEDICINE.
This leaflet contains
concise information about the medicine. If you have further questions,
refer to the doctor or
pharmacist.
This medicine has been prescribed for the treatment of your ailment.
Do not pass it on to others. It
may harm them even if it seems to you that their ailment is similar.
In addition to the leaflet, the Rivaroxaban Propharm 10 mg is provided
with a patient safety
information card.
This card contains important information that you must know and abide
by before starting and
during treatment with Rivaroxaban Propharm 10 mg.
Read the Patient Safety Information Card and the patient leaflet
before starting to use the
preparation.
Keep the card and leaflet for further reading if necessary.
1. WHAT IS THE MEDICINE INTENDED FOR?
Rivaroxaban Propharm 10 mg is intended for:
-
preventing venous thrombosis in adults following elective hip or knee
replacement surgery.
-
preventing recurrence of blood clots in the veins of the legs (deep
vein thrombosis) and in the
blood vessels of the lungs (pulmonary embolism) following the
completion of at least 6 months
therapy for a previous deep vein thrombosis or pulmonary embolism.
THERAPEUTIC GROUP: Rivaroxaban Propharm 10 mg belongs to a group of
medicines called
antithrombotic agents and acts by lowering the tendency to form blood
clots by blocking a factor
involved in the blood-clotting process (Factor Xa).
2. BEFORE USING THE MEDICINE
DO NOT USE THE MEDICINE IF:
•
you are sensitive (allergic) to rivaroxaban or to any of the other
ingr